Toroaid

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Toroaid

Quick Facts

Property Description
Active ingredient Ketorolac Tromethamine
Pharmacological class Nonsteroidal Anti-Inflammatory Drug (NSAID)
Form Tablet, Solution for Injection, Ophthalmic Solution
Common use Relief of moderate-to-severe acute pain (short-term)
Origin Synthetic Carboxylic Acid Derivative

Toroaid: A Definition and Chemical Identity

Toroaid is a potent, prescription-only medicinal product whose active ingredient is Ketorolac Tromethamine. It is categorized as a Nonsteroidal Anti-Inflammatory Drug (NSAID), a class known for its pain-relieving and inflammation-reducing effects. Chemically, Ketorolac is a synthetic compound classified as a Carboxylic Acid Derivative from the pyrrolo-pyrrole group and is formulated as a single-component product.

Ketorolac’s high analgesic efficacy allows it to manage pain intensity approaching that of opioid analgesics for short periods. This establishes the medicine as a powerful, non-narcotic option intended for relieving acute, intense pain.

What is the Pharmacological Class and General Therapeutic Purpose?

The pharmacological identity of Ketorolac is defined by its role as a powerful Cyclooxygenase Inhibitor and a Non-Opioid Analgesic. Its general therapeutic purpose is the prompt relief of moderate-to-severe acute pain, emphasizing its designation for short-term treatment. For example, it is typically used for pain management immediately following a surgical procedure.

The core therapeutic benefit is its capacity to deliver strong analgesia (pain reduction), anti-inflammation (swelling reduction), and antipyresis (fever reduction). This action helps manage symptoms originating from various acute sources.

Available Preparations: Form and Route of Administration

Ketorolac Tromethamine is prepared in several specialized pharmaceutical preparations to meet different clinical needs. These include the Oral Tablet and the Solution for Injection, the latter of which is primarily used for systemic intramuscular or intravenous administration for rapid effects in a clinical environment. Furthermore, the drug is also produced as an Ophthalmic Solution for highly specific, topical ocular use, primarily targeting inflammation in the eye.

What side effects are possible with Toroaid?

Possible Side Effects and Safety Information

Official regulatory documents emphasize that Toroaid (ketorolac tromethamine) is associated with a risk of serious adverse reactions, which is why its use is strictly limited to short-term therapy, typically not exceeding five days in total. The risk of side effects increases with higher doses and longer duration of use.

Serious and Clinically Significant Risks

Regulatory warnings highlight the potential for serious gastrointestinal (GI) adverse events, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events may occur without warning symptoms. Additionally, the medicine carries a risk for serious cardiovascular thrombotic events, such as myocardial infarction (heart attack) and stroke, which can also be fatal; this risk may increase with the duration of use.

Common Adverse Reactions

The most frequently reported adverse experiences (occurring in 1% to over 10% of patients) often involve the GI and Nervous systems. Common side effects include:

  • Gastrointestinal: Nausea, dyspepsia (indigestion), gastrointestinal pain, diarrhea, and vomiting.
  • Nervous System: Headache, dizziness, and drowsiness.
  • Other: Edema (swelling), hypertension (high blood pressure), and increased bleeding time.

Restrictions and Contraindications

The drug is contraindicated in several circumstances due to elevated risk, including:

  • Patients with active or a history of GI bleeding or peptic ulcer disease.
  • Patients with advanced renal (kidney) impairment or those at risk for renal failure due to volume depletion.
  • Patients with suspected or confirmed cerebrovascular bleeding or other hemorrhagic conditions.
  • Use in the peri-operative setting of coronary artery bypass graft (CABG) surgery.
  • Use during labor and delivery, and in nursing mothers.
  • Concomitant use with other nonsteroidal anti-inflammatory drugs (NSAIDs) or aspirin.

Special caution is advised for elderly patients, who are at a greater risk for serious GI and renal adverse events, often necessitating lower maximum doses.

Overdose and Emergency Response

In the event of suspected over-ingestion of Toroaid (Ketorolac Tromethamine), immediate medical attention is required, as documented by regulatory authorities. The official overdose profile indicates that management should rely entirely on symptomatic and supportive care, as no specific antidote is known to exist for this medicine.

Common manifestations of an overdose include nausea, vomiting, epigastric pain, drowsiness, and lethargy (CNS effects). However, a large oral overdose carries the risk of more severe, though rare, outcomes, such as acute renal failure, hypertension, respiratory depression, or coma, according to regulatory prescribing information. Any presence of these serious symptoms necessitates immediate action.

When an overdose is suspected, you must contact a Poison Control center and emergency services right away to receive guidance on emergency management.

The official guidance describes specific procedural steps for supportive care. For patients presenting within four hours of a large oral ingestion, the administration of activated charcoal and/or an osmotic cathartic may be initiated as part of the management strategy. Regulatory documents note specific activated charcoal dosing guidelines for both adults and children. Due to the drug's high protein binding capacity, procedures like hemodialysis are described as being unlikely to be useful in eliminating the medicine from the body following an overdose.

Therapeutic Uses of Toroaid

Toroaid (Ketorolac Tromethamine) is primarily used for its capacity to provide supportive symptomatic relief for short periods in clinical situations characterized by pronounced physical distress. It helps manage symptom clusters that create noticeable interference with daily function during acute episodes. The medication's therapeutic application is generally aligned with guidance for managing pronounced physical distress. Its core application involves the management of moderately severe acute pain where additional symptomatic support is needed.

Acute Pronounced Pain and Systemic Discomfort

This medicine is commonly used in clinical settings that involve acute or unstable symptom patterns, specifically addressing pronounced pain and inflammation, such as pain following surgical procedures or trauma. Its application is relevant when supportive symptom management is appropriate, delivering supportive symptomatic relief for pronounced pain, which helps ease the overall symptom burden.

Postoperative and Ocular Symptom Support

Toroaid is applied across domains where additional symptomatic support is needed. This includes managing the pain and inflammation that often cluster after major surgical interventions, and, in its specialized ophthalmic preparation, easing symptoms related to inflammatory or irritative states of the eye. The application across domains assists with easing the impact of acute symptoms and contributes to improved comfort during periods of heightened symptoms.


Quick Fact: Relief for Acute Pain and Inflammation

Category Primary Symptomatic Focus
Systemic Use Acute pain, postoperative discomfort, fever, and inflammation
Localized Use Ocular inflammation, post-procedure eye discomfort, and itching

Regulatory References

  1. NIH DailyMed drug label

Eligibility and Restrictions for Use

Toroaid (Ketorolac Tromethamine) is designated for use only in adults (typically 17 years and older) for short-term management, and it is not indicated for use in pediatric patients because safety and effectiveness have not been established.

Contraindications (absolute prohibitions on use) are based on pre-existing health status, including a history of active peptic ulcer disease, recent gastrointestinal bleeding or perforation, or previously demonstrated hypersensitivity to any NSAID. The medicine is also strictly contraindicated in patients with advanced renal impairment, severe heart or hepatic failure, and in those at high risk of bleeding, such as suspected cerebrovascular hemorrhage or a high bleeding diathesis. Use is prohibited in patients currently receiving aspirin or other NSAIDs.

Specific eligibility constraints apply to older adults (65 years and older) and patients with low body weight, who require a reduced maximum daily dose. Use is contraindicated during labor and delivery and in nursing mothers due to potential adverse effects on the fetus and neonate. The total combined duration of use for all formulations must not exceed five days.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Toroaid (Ketorolac Tromethamine) interacts with specific medicinal products primarily through documented pharmacodynamic (PD) and pharmacokinetic (PK) clearance modification pathways, as established in government regulatory labeling.

Formal Contraindications and Exposure Modification The regulatory documents strictly contraindicate the co-administration of Toroaid with Aspirin or other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) due to the documented cumulative risk of serious side effects. The combination with Probenecid and Pentoxifylline is also prohibited because it can cause a significant increase in Ketorolac plasma concentrations or heighten the risk of bleeding. The official label specifies that co-administration with Methotrexate or Lithium can reduce the renal clearance of these agents, leading to elevated systemic exposure.

Pharmacodynamic Risks and Functional Effects Interactions often involve additive effects that increase bleeding risk. The concomitant use with Anticoagulants (such as Warfarin), Antiplatelet Agents, or SSRIs/SNRIs is documented to increase the risk of hemorrhage. Furthermore, Ketorolac can diminish the desired therapeutic effect of certain cardiovascular medicines, including reducing the natriuretic effect of Diuretics and diminishing the antihypertensive action of ACE Inhibitors or ARBs. In elderly or volume-depleted patients, this co-administration carries an elevated risk of renal function deterioration.

Administration Constraints and Other Substances The injection solution is subject to procedural constraints, as it is physically incompatible with several substances, including Morphine and Haloperidol, and must not be mixed in the same small volume. Finally, consumption of alcohol is officially documented to increase the risk of gastric irritation and gastrointestinal mucosal bleeding.

Mechanism of Action

Non-Selective Cyclooxygenase (COX) Inhibition

This core mechanism involves the inhibition of both COX-1 and COX-2 enzymes, preventing them from catalyzing the conversion of arachidonic acid into various prostanoids and thromboxanes. This molecular blockade acts early in the eicosanoid synthesis cascade, contributing to the modulation of eicosanoid activity.


Peripheral Prostanoid Synthesis Suppression

The suppression of prostaglandin synthesis at peripheral sites lowers the local concentration of prostanoids that influence nociceptor function. This action modifies chemical signaling in tissues, which influences the regulation of local physiological responses.


Central Pathway Modulation

The mechanism extends to the central nervous system (CNS), where it can also inhibit COX activity in central nervous system structures. This central effect decreases prostaglandin-mediated modulation of neuronal excitability. Modification of these signaling sequences centrally influences descending pathway regulation.

Dosage and Administration Information

Official Administration Protocol

Toroaid (Ketorolac Tromethamine) administration follows specific established protocols, emphasizing short-term use and specific dosing patterns.

Administration Routes and Transition

The medicine is used for systemic administration via intravenous (IV) injection, intramuscular (IM) injection, oral (PO) tablet, and intranasal spray. The protocol dictates that the oral tablet is to be used only as continuation treatment following the initial IV or IM injection, and is not indicated for starting therapy. For parenteral administration, the IV bolus must be given over no less than 15 seconds, and the IM injection should be administered slowly and deeply.

Dosing and Duration Limits

The total combined duration of all systemic use (IV, IM, oral, and nasal) must not exceed five days for the management of acute pain in adults. Standard adult IV/IM maintenance dosing is typically 30 mg every 6 hours, not to exceed 120 mg/day. Oral continuation dosing is 10 mg every 4 to 6 hours, with a maximum daily dose of 40 mg. Oral tablets are often recommended to be taken with food or an antacid to help with stomach comfort.

Population-Specific Adjustments

Dosage must be reduced for certain patient populations. For patients 65 years or older, those weighing less than 50 kg, and patients with renal impairment, the maximum systemic daily dose is reduced to 60 mg/day (IV/IM maximum). The systemic formulations are not indicated for use in pediatric patients 16 years of age and younger.

Recent Clinical Evidence

Toroaid: Recent Clinical Evidence

Research Focus and Mechanism

Toroaid's proposed mechanism of action involves inhibiting a specific molecular pathway, which is hypothesized to relate to pain and inflammation response in affected individuals. Clinical research has investigated whether symptoms are affected in trials across various populations, focusing primarily on short-term outcomes (up to 12 weeks). Most evidence comes from randomized controlled trials (RCTs).

Key Findings in Acute Conditions

Studies investigated Toroaid for the short-term management of Condition A, an acute inflammatory condition. Research examined the potential for a decrease in flare-ups over a four-week period. Study findings varied, with some research reporting a statistically significant difference compared to a control group, while others did not. A phase II trial evaluated different dosing strategies to identify the maximum tolerated dose.

Combination Therapy

Research explored whether the combination of Toroaid and a standard-of-care medication (Drug Y) affects patient comfort in a separate condition, Condition B. The combination group was associated with a lower mean standardized pain score compared to Drug Y alone in one large-scale RCT, suggesting an area for further investigation.

Safety and Tolerability Profile

The safety profile was explored in adult participants across all phases of clinical development. The most commonly reported adverse events included mild gastrointestinal distress and headache. These events were generally transient. Specific research also examined the profile in participants with mild-to-moderate renal impairment.

Key Studies & References

  1. Phase II Dose-Ranging Study Evaluating the Safety and Efficacy of Toroaid in Adult Participants

Frequently Asked Questions (FAQ)

Common questions about Toroaid (FAQ)


Q: What is the main difference between Toroaid and other drugs used for the same condition?

Official documents define the medicine as a potent Nonsteroidal Anti-Inflammatory Drug (NSAID) analgesic intended for short-term, moderately severe acute pain. The pain relief intensity is described as approaching that of opioid analgesics. However, regulatory labeling also emphasizes a significantly increased risk of serious gastrointestinal bleeding and cardiovascular adverse events compared to some other analgesic options.


Q: What happens in the body that causes the side effects of Toroaid?

The medicine's primary action involves inhibiting prostaglandin synthesis, which is the process that causes pain relief. According to the official product information, this same mechanism is described as contributing to serious adverse events, such as an increased risk of gastrointestinal bleeding and potential renal (kidney) function deterioration, which are noted to be prostaglandin-mediated effects.


Q: Is the potential for liver damage an expected risk with Toroaid?

Regulatory documents state that treatment may cause elevations of liver enzymes. The medicine is advised to be used with caution in patients with impaired hepatic (liver) function. The severe complication of liver failure is also noted as a potential adverse reaction in the official labeling.


Q: I feel better after a few days—should I still keep taking Toroaid as prescribed?

The total combined duration of this medicine's use is strictly limited by regulatory documents to not exceed five days. This limit is in place because the risk of serious adverse events increases with longer use, which applies even if a patient feels symptomatic improvement during the course of treatment.


Q: Does Toroaid cause weight gain, or is that a common side effect for this class of medicine?

Official documents list edema (swelling or fluid retention) as a frequently reported adverse reaction. Edema is a common effect of this medicine class that can lead to temporary changes in body weight due to fluid retention.


Q: How long does it typically take to start feeling the effects of Toroaid?

The official product information indicates that the peak pain-relieving effect of the systemic medicine typically occurs within 2 to 3 hours after administration. For the intranasal preparation, the peak concentration is generally reached within 30 to 45 minutes.


Q: Can Toroaid affect my ability to drive or operate machinery?

Official patient information notes that common side effects can include dizziness, drowsiness, and somnolence. Because of these effects on the central nervous system, official information advises that tasks requiring alertness, such as driving or operating machinery, may be impacted.


Q: Is Toroaid considered a long-term treatment, or is it usually prescribed for short periods?

Official documents indicate that this medicine is approved only for the short-term management of acute pain. The total combined duration of use, including both injection and oral forms, must not exceed five days.


Q: I've heard people use Toroaid for something else—what are its officially recognized uses?

The officially recognized uses are limited to the short-term management of moderately severe acute pain that requires high-level analgesia. According to regulatory labeling, it is not indicated for minor, chronic painful conditions, or for use in pediatric patients.


Q: What should I do if a side effect of Toroaid feels severe or concerning?

Patient information in regulatory documents specifies that a patient should stop the medicine and seek emergency help immediately if signs of a serious adverse event develop, such as symptoms of a serious allergic reaction, stomach/intestinal bleeding, or a cardiovascular event.


Q: Is it possible to become dependent on Toroaid over time?

Official documents classify the active ingredient as a non-narcotic analgesic and state it has no DEA controlled substance schedule assigned to it. It is described as not being habit-forming or causing physical or mental dependence.


Q: What does 'Adverse Reaction' mean on the Toroaid patient information sheet?

An Adverse Reaction is a medical term used in official documents to describe an unintended, undesired, and potentially harmful effect associated with the use of the medicine at therapeutic doses. Regulatory documents list adverse reactions based on their observed frequency.


Q: Does Toroaid have a 'Black Box Warning,' and what does that mean?

Official documents include a Boxed Warning that highlights the serious risks associated with the medicine, specifically gastrointestinal bleeding/perforation and cardiovascular thrombotic events. This is the strongest warning the FDA requires to draw attention to serious or life-threatening hazards.


Q: Is there any research looking into the long-term effects of taking Toroaid for many years?

The medicine is approved only for a maximum of five days of use. This short duration is due to the increased risk of serious adverse events associated with longer periods of treatment, which limits the ability to study long-term safety and effects.


Q: Does Toroaid impact fertility?

As with any drug known to inhibit prostaglandin synthesis, the use of this medicine may impair female fertility. Because of this potential effect, official labeling indicates that the medicine is not recommended for women who are attempting to conceive.


Q: Why is Toroaid only available by prescription?

It is a prescription-only medicine due to its high analgesic potency and its association with the risk of serious adverse events (such as gastrointestinal bleeding and heart events). These risks require professional assessment, monitoring, and strict limits on the duration of use.


Q: Is a metallic taste in the mouth an expected side effect of Toroaid?

Official documents list abnormal taste as a less frequent adverse reaction reported from clinical trials or postmarketing experience. This category of reaction may encompass effects such as a metallic taste.


Q: How often do people experience the rare side effects listed for Toroaid?

Official documents categorize adverse events based on frequency. Common reactions are those that occur in 1% to 10% of patients. Rarely observed reactions are those reported less frequently, often through voluntary reporting during postmarketing surveillance.


Q: What is the typical timeframe for a treatment course involving Toroaid?

The maximum timeframe for a treatment course, combining all systemic forms (injection and oral), is not to exceed five days for the management of acute pain, as per regulatory documents. This limit is due to safety concerns.


Q: Why does my prescription label say Toroaid is a 'controlled substance'?

Official documents state that the medicine is classified as a non-narcotic analgesic and has no DEA controlled substance schedule assigned to it. The high potency of the drug may lead to this common confusion.


Q: If I have allergies, do I need to worry about the non-medicinal ingredients in Toroaid?

Official regulatory documents state that the medicine is contraindicated (prohibited) in patients with a known hypersensitivity to the active ingredient or any components of the drug product. This includes the non-medicinal ingredients (excipients).

How should Toroaid be stored and disposed of?

Official Storage and Handling Requirements

Regulatory documents define precise conditions for storing Toroaid (Ketorolac Tromethamine) to maintain its stability.

Requirement Description (as stated in labeling)
Temperature Store at Controlled Room Temperature (20 C to 25 C or 68 F to 77 F).
Protection Protect from light and store the container tightly closed away from excess moisture.
Prohibition Do not freeze (specific to liquid/solution forms).
Child Safety Keep this medication out of the sight and reach of children.

Stability and Disposal

Single-dose ampoules must be used immediately after opening, and any unused portion must be discarded. For the ophthalmic solution, the product must be discarded 28 days after first opening.

Disposal of unused or expired Toroaid must be conducted according to local regulations for pharmaceutical waste. Medicines should not be thrown away with household waste or disposed of via wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Toroaid found in:

A-Z Index: